Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1

Interventions

pembrolizumab 166 Carboplatin 132 Cisplatin 81 Paclitaxel 78 Gemcitabine 77 Pemetrexed 72 Bevacizumab 63 Docetaxel 54 Fluorouracil 49 Oxaliplatin 48 Dexamethasone 46 durvalumab 43 atezolizumab 39 Leucovorin 39 130-nm albumin-bound paclitaxel 39 Capecitabine 37 Cetuximab 36 Rituximab 35 Nivolumab 35 Fulvestrant 35 Cyclophosphamide 34 Injections 31 venetoclax 29 Prednisone 28 Lenalidomide 28 enzalutamide 27 pomalidomide 25 Letrozole 25 Irinotecan 25 daratumumab 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × tisotumab vedotin × 30 days × Clear all

NCT06459180 2026-05-27

TroFuse-020

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡